CheckMate032TMB-strelka
Tumor Mutation Burden and Efficacy of Nivolumab Monotherapy and in Combination With Ipilimumab in Small Cell Lung Cancer using strelka somatic variant calls
Whole exome sequencing was used to evaluate the impact of tumor mutation burden (TMB) on efficacy of nivolumab monotherapy or combined with ipilimumab in patients with SCLC from the nonrandomized or randomized cohorts of CheckMate 032.
Whole exome sequencing was used to evaluate the impact of tumor mutation burden (TMB) on efficacy of nivolumab monotherapy or combined with ipilimumab in patients with SCLC from the nonrandomized or randomized cohorts of CheckMate 032.